New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

0 Views
administrator
administrator
07/08/23

Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next